INTELGENX TECHNOLOGIES
INTELGENX TECHNOLOGIES
Aktie · US45822R1014 · A0RP0X (XTSX)
Übersicht
Kein Kurs
n/a
Free Float & Liquidität
Free Float 77,58 %
Shares Float 135,51 M
Ausstehende Aktien 174,66 M
Asset Allocation
VermögenswertAnteil %
Bond93,42 %
NotClassified5,29 %
Cash1,29 %
Stock non-US0,00 %
Other0,00 %
Stock US0,00 %
Die größten Positionen
SymbolISINNameAnteil %
BOEING CO SR UN.. 2,84 %
BANK OF AMERICA.. 2,77 %
AT+T INC SR UNS.. 2,17 %
CREDIT SUISSE G.. 1,94 %
MORGAN STANLEY .. 1,91 %
STATE STREET IN.. 1,86 %
BAT CAPITAL COR.. 1,84 %
WELLS FARGO + C.. 1,78 %
JPMORGAN CHASE .. 1,77 %
ANHEUSER BUSCH .. 1,71 %
Regionen Verteilung
RegionAnteil %
Africa/Middle East0,00 %
Asia Developed0,00 %
Asia Emerging0,00 %
Australasia0,00 %
Europe Developed0,00 %
Europe Emerging0,00 %
Japan0,00 %
Latin America0,00 %
North America0,00 %
United Kingdom0,00 %
Sektor Verteilung
SektorAnteil %
Grundstoffe0,00 %
Verbrauchsgüter0,00 %
Finanzdienstleistungen0,00 %
Immobilien0,00 %
Telekommunikation0,00 %
Energie0,00 %
Industrieunternehmen0,00 %
Technologie0,00 %
Basiskonsumgüter0,00 %
Gesundheitswesen0,00 %
Firmenprofil zu INTELGENX TECHNOLOGIES Aktie
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Erhalte tagesaktuelle Insights vom finAgent über INTELGENX TECHNOLOGIES
Fonds Stammdaten
Emittent Principal
Wertpapierart ETF
Name Principal Exchange-Traded Funds - Principal Investment Grade Corporate Active ETF
Fondswährung USD
Kategorie Corporate Bond
Morningstar Rating 4
Fonds Kennzahlen
Fondgröße 486.880,38 EUR
Anlagestrategie
The investment seeks to provide current income and, as a secondary objective, capital appreciation. The fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets, plus any borrowings for investment purposes, in investment grade corporate bonds and other fixed income securities at the time of purchase. Investment grade securities are rated BBB- or higher by S&P Global Ratings (S&P Global) or Baa3 or higher by Moody's Investors Service, Inc. (Moody's) or, if unrated, of comparable quality in the opinion of those selecting such investments.

Unternehmensdaten

Name INTELGENX TECHNOLOGIES
Firma IntelGenx Technologies Corp.
Website https://www.intelgenx.com
Heimatbörse XTSX TSX-V
WKN A0RP0X
ISIN US45822R1014
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dwight Gorham
Marktkapitalisierung 42 Mio
Land Kanada
Währung EUR
Mitarbeiter -
Adresse 6420 Abrams, H4S 1Y2 Montreal
IPO Datum 2008-05-27

Ticker Symbole

Name Symbol
TSX IGX.TO
Weitere Aktien
Investoren, die INTELGENX TECHNOLOGIES halten, haben auch folgende Aktien im Depot:
HESSEN SCHA.21/31
HESSEN SCHA.21/31 Anleihe
HSBC BANK PLC CALLABLE ACCRETING NTS 01/06/39
HSBC BANK PLC CALLABLE ACCRETING NTS 01/06/39 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025